← Evidence map

ArticlePharmaceuticals (Basel, Switzerland)2024

Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study).

Yuichi Tamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study). | OpenQuestion